

## **Australia Diabetes Care Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029**

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

### **AVAILABLE LICENSES:**

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

### **Report description:**

The Australia Diabetes Care Drugs Market size is estimated at USD 815.19 million in 2024, and is expected to reach USD 972.88 million by 2029, growing at a CAGR of 3.60% during the forecast period (2024-2029).

The COVID-19 epidemic boosted the expansion of the Australia Diabetes Care Drugs Market. Diabetes patients infected with COVID-19 may have high blood glucose levels, irregular glucose variability, and diabetic complications. According to the Australian Government Department of Health and Aged Care, there have been 92,35,681 confirmed cases of COVID-19 in Australia since the pandemic's commencement in July 2022. Diabetes prevalence in adults with COVID-19 produced a substantial increase in COVID-19 severity and mortality in people with type 1 (T1DM) or type 2 diabetes mellitus (T2DM), particularly in connection with poor glycemic control. While new-onset hyperglycemia and diabetes (both T1DM and T2DM) have become more recognized in the setting of COVID-19 and have been linked to worse outcomes. To minimize aggravation, a patient's blood glucose should be checked and maintained on a regular basis, emphasizing the significance of diabetes care medicines.

Obesity, a poor diet, and physical inactivity are all contributing to a rise in the number of newly diagnosed Type 1 and Type 2 diabetes cases. The fast-rising incidence and prevalence of diabetes patients, as well as healthcare spending in industrialized nations, are indicators of increased use of diabetic care products. Furthermore, rising diabetes incidence and increased usage of insulin delivery devices are boosting market expansion. Leading manufacturers are focused on technical advancements and the creation of improved goods to achieve a significant market share.

Australia Diabetes Care Drugs Market Trends

Oral-Anti Diabetes Drugs is Having the Highest Market Share in the Current Year.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

The Oral-Anti Diabetes Drugs segment is expected to increase with a CAGR of over 5% during the forecast period, mainly due to the demand from the diabetes population, which was more than 1.4 million by the end of the current year.

According to the Australian National Health Survey 2020-2021, one out of every 20 persons (5.3%) suffers from diabetes. Type 2 diabetes was the most frequent (85.5%), followed by Type 1 diabetes (11.0%) and diabetes not known by the individual reporting (4.1%). Diabetes patients are diagnosed with blood glucose imbalances that do not follow conventional blood glucose values. The common lab diagnostic tests can only assist physicians in diagnosing the condition. Patients whose glucose levels fluctuate more often should monitor it every day. Patients who use insulin must monitor their blood glucose levels often and alter insulin dosages or change medications as needed. People with type 2 diabetes who do not use insulin need oral drugs frequently. The Australian National Diabetes Strategy was developed in response to diabetes and outlined how existing limited healthcare resources across all levels of government might be effectively integrated and targeted. This strategy identifies the most effective and suitable strategies to decrease the community burden of diabetes and sets the standard for diabetes prevention, care, and research on a global scale.

Diabetes pills are not insulin taken orally. People with type 2 diabetes are frequently prescribed drugs, including insulin, to help them control their blood glucose levels. Most of these drugs are taken as pills; others are administered through injection. Tablets and injections are meant to supplement, not replace, a balanced diet and frequent physical exercise.

Through the Australian government's encouragement, the usage of drugs increased over the forecast period.

The rising prevalence of diabetes in Australia is boosting the country's diabetes drug market.

Diabetes prevalence occurred in Australia more than quadrupled between 1991 and 2021. In current, Australia includes around more than 2 million diabetes patients. According to Mordor Intelligence statistics, Type-2 diabetes patients accounted for most of the overall diabetic population in Australia in the current year. Nevertheless, diabetes is far more prevalent in Australia than in many other nations. One of the primary goals of diabetes therapy is to keep blood glucose levels within a certain target range. It can be accomplished by balancing food, activity, lifestyle, and diabetes medications. Blood glucose monitoring results give the information needed to establish the appropriate diabetes care approach. Maintaining target blood glucose levels can help minimize a person's chance of acquiring various diabetes-related problems such as diabetic retinopathy, heart disease, renal disease, etc. The frequency with which patients with diabetes who take insulin check their blood glucose levels varies depending on various factors.

Because of the early age and longer diabetes duration, youth are more likely to get diabetes at a younger age, lowering their quality of life, shortening their life expectancy, and increasing societal healthcare expenditures. As a result, the demand for diabetes care drugs is growing, and their acceptance rate is increasing, driving the market. In addition, with increased awareness among Type 2 diabetes patients, the need for Diabetes drugs is developing rapidly.

Thus, the above factors are expected to drive the market growth over the forecast period.

#### Australia Diabetes Care Drugs Industry Overview

The diabetes drugs market is moderately fragmented, with few significant generic players. A few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb, dominate the insulin drugs and Sglt-2 drugs market. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, players are tapping into new markets to increase their market shares. It is especially applicable in emerging economies where the demand is very high

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

compared to the supply.

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

## **Table of Contents:**

### 1 INTRODUCTION

- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study

### 2 RESEARCH METHODOLOGY

### 3 EXECUTIVE SUMMARY

### 4 MARKET DYNAMICS

- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
- 4.4 Porter's Five Forces Analysis
  - 4.4.1 Bargaining Power of Suppliers
  - 4.4.2 Bargaining Power of Consumers
  - 4.4.3 Threat of New Entrants
  - 4.4.4 Threat of Substitute Products and Services
  - 4.4.5 Intensity of Competitive Rivalry

### 5 MARKET SEGMENTATION

- 5.1 Oral Anti-diabetic drugs
  - 5.1.1 Biguanides
    - 5.1.1.1 Metformin
  - 5.1.2 Alpha-Glucosidase Inhibitors
    - 5.1.2.1 Alpha-Glucosidase Inhibitors
  - 5.1.3 Dopamine D2 receptor agonist
    - 5.1.3.1 Bromocriptin
  - 5.1.4 SGLT-2 inhibitors □
    - 5.1.4.1 Invokana (Canagliflozin)
    - 5.1.4.2 Jardiance (Empagliflozin)
    - 5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
    - 5.1.4.4 Suglat (Ipragliflozin)
  - 5.1.5 DPP-4 inhibitors
    - 5.1.5.1 Onglyza (Saxagliptin)
    - 5.1.5.2 Tradjenta (Linagliptin)
    - 5.1.5.3 Vipidia/Nesina (Alogliptin)
    - 5.1.5.4 Galvus (Vildagliptin)
  - 5.1.6 Sulfonylureas
    - 5.1.6.1 Sulfonylureas

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1.7 Meglitinides
  - 5.1.7.1 Meglitinides
- 5.2 Insulins
  - 5.2.1 Basal or Long Acting Insulins
    - 5.2.1.1 Lantus (Insulin Glargine)
    - 5.2.1.2 Levemir (Insulin Detemir)
    - 5.2.1.3 Toujeo (Insulin Glargine)
    - 5.2.1.4 Tresiba (Insulin Degludec)
    - 5.2.1.5 Basaglar (Insulin Glargine)
  - 5.2.2 Bolus or Fast Acting Insulins
    - 5.2.2.1 NovoRapid/Novolog (Insulin Aspart)
    - 5.2.2.2 Humalog (Insulin Lispro)
    - 5.2.2.3 Apidra (Insulin Glulisine)
  - 5.2.3 Traditional Human Insulins
    - 5.2.3.1 Novolin/Actrapid/Insulatard
    - 5.2.3.2 Humulin
    - 5.2.3.3 Insuman
  - 5.2.4 Biosimilar Insulins
    - 5.2.4.1 Insulin Glargine Biosimilars
    - 5.2.4.2 Human Insulin Biosimilars
- 5.3 Non-Insulin Injectable drugs
  - 5.3.1 GLP-1 receptor agonists
    - 5.3.1.1 Victoza (Liraglutide)
    - 5.3.1.2 Byetta (Exenatide)
    - 5.3.1.3 Bydureon (Exenatide)
    - 5.3.1.4 Trulicity (Dulaglutide)
    - 5.3.1.5 Lyxumia (Lixisenatide)
  - 5.3.2 Amylin Analogue
    - 5.3.2.1 Symlin (Pramlintide)
- 5.4 Combination drugs
  - 5.4.1 Insulin combinations
    - 5.4.1.1 NovoMix (Biphasic Insulin Aspart)
    - 5.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
    - 5.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
  - 5.4.2 Oral Combinations
    - 5.4.2.1 Janumet (Sitagliptin and Metformin)

## 6 MARKET INDICATORS

- 6.1 Type-1 Diabetic Population
- 6.2 Type-2 Diabetic Population

## 7 COMPETITIVE LANDSCAPE

- 7.1 COMPANY PROFILES
  - 7.1.1 Takeda
  - 7.1.2 Novo Nordisk
  - 7.1.3 Pfizer
  - 7.1.4 Eli Lilly

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.1.5 Janssen Pharmaceuticals

7.1.6 Astellas

7.1.7 Boehringer Ingelheim

7.1.8 Merck And Co.

7.1.9 AstraZeneca

7.1.10 Bristol Myers Squibb

7.1.11 Novartis

7.1.12 Sanofi

7.2 COMPANY SHARE ANALYSIS

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Australia Diabetes Care Drugs - Market Share Analysis, Industry Trends & Statistics,  
Growth Forecasts 2018 - 2029**

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-05"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

